FGP
LGND icon

Freestone Grove Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Freestone Grove Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,817
Closed -$562K – 1200
2026
Q1 		$562K Sell
2,817
-50
-2% -$9.89K ﹤0.01% 580
2025
Q4 		$542K Buy
+2,867
New +$551K ﹤0.01% 558

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Freestone Grove Partners's LGND Position: Q2 2026 in Review

Freestone Grove Partners sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 2,817 shares — an estimated $562K sold.

Freestone Grove Partners first reported a position in LGND in Q4 2025 and held it in 2 quarters. The position peaked at $562K in Q1 2026. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Freestone Grove Partners reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 2,817 Ligand Pharmaceuticals shares in Q2 2026, an estimated $562K.
  • Freestone Grove Partners first reported a position in Ligand Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Freestone Grove Partners's Ligand Pharmaceuticals position peaked at $562K in Q1 2026.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.